51 results about "Clinical marker" patented technology

The present invention relates to methods, monitors and systems measuring lysophosphatidylcholine, its derivatives and / or procalcitonin as well as at least one clinical marker (e.g. temperature or respiration rate) and / or at least one biomarker for the early detection of sepsis in a subject.

An MRI image processing and analysis system may identify instances of structure in MRI flow data, e.g., coherency, derive contours and / or clinical markers based on the identified structures. The system may be remotely located from one or more MRI acquisition systems, and perform: perform error detection and / or correction on MRI data sets (e.g., phase error correction, phase aliasing, signal unwrapping, and / or on other artifacts); segmentation; visualization of flow (e.g., velocity, arterial versus venous flow, shunts) superimposed on anatomical structure, quantification; verification; and / or generation of patient specific 4-D flow protocols. An asynchronous command and imaging pipeline allows remote image processing and analysis in a timely and secure manner even with complicated or large 4-D flow MRI data sets.

A sensor is provided that is appropriate for optical detection of dissolved carbon dioxide. Such a sensor may be used for transcutaneous detection of carbon dioxide in the tissue. Alternatively, such sensors may be inserted into the tissue. Detection of dissolved carbon dioxide in the tissue may serve as a useful clinical marker for physicians.

A method of detecting whether or not a body chamber has an abnormal structure or function including: (a) providing a stack of images as input to a system comprising one or more hardware processors configured to obtain a stack of medical images comprising at least a representation of the body chamber inside the patient; to obtain a region of interest using a convolutional network trained to locate the body chamber, wherein the region of interest corresponds to the body chamber from each of the medical images; and to infer a shape of the body chamber using a stacked auto-encoder (AE) network trained to delineate the body chamber, wherein the AE network segments the body chamber; (b) operating the system to detect the body chamber in the images using deep convolutional networks trained to locate the body chamber, to infer a shape of the body chamber using a stacked auto-encoder trained to delineate the body chamber, and to incorporate the inferred shape into a deformable model for segmentation; and (c) detecting whether or not the body chamber has an abnormal structure, wherein an abnormal structure is indicated by a body chamber clinical indicia that is different from a corresponding known standard clinical indicia for the body chamber.

The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and / or treating CVD complications. The invention additionally relates to kits comprising lipids and / or an antibody thereto, for use in the prediction and / or diagnosis of CVD complications.

The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and / or an antibody thereto, for use in the prediction and / or diagnosis of statin-induced muscle toxicity.